Latest Rosetta Genomics Stories
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact 1-888-522-7971, or visit the company's website...
REHOVOT, Israel and JERSEY CITY, New Jersey and PHILADELPHIA, December 22 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its second diagnostic test, miRview(TM) mets. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. The test identifies 25 different tumor types, including, but not limited to, those from the...
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, December 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its first diagnostic test, miRview(TM) squamous. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact 1-888-522-7971, or visit the company's website...
REHOVOT, Israel and JERSEY CITY, New Jersey, December 5 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today that it will present at RBC Capital Markets 2008 Healthcare Conference on Thursday, December 10, from 2:30-3:35 pm EST at the Westin Hotel in New York. A live audio webcast of the presentation will be available on the "Investors" section of the company's website,...
REHOVOT, Israel and JERSEY CITY, New Jersey, December 5 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostic company leveraging microRNAs as biomarkers, reported today its consolidated financial results for the quarter ended September 30, 2008 and business highlights. The company recorded revenues for the third quarter of 2008 of $705,000. These revenues were recorded from the date of acquisition of Parkway Clinical Laboratories at the...
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research findings in the journal Cancer Cell demonstrating a key role of microRNAs in regulating angiogenesis pathways in cancer, specifically in malignant brain tumors. Angiogenesis is a physiological process required for the growth and...
Response Genetics, a developer of clinical diagnostic tests for cancer, has announced an agreement with NeoGenomics Laboratories, a clinical laboratory service provider of oncology focused genetic diagnostic tests, and the formation of its own sales team, as part of its sales strategy to offer its ResponseDX: Colon and ResponseDX: Lung tests nationwide. ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to...
Rosetta Genomics has announced positive results of a study conducted by its scientists describing the identification of microRNA biomarkers in blood serum. The findings demonstrate that microRNAs have the potential to be used as clinical biomarkers for a wide range of indications in cancer and women's health, the company said. Using its proprietary extraction and quantification methods, Rosetta Genomics said that it is now advancing the development of a blood-based test which will utilize...
REHOVOT, Israel and JERSEY CITY, New Jersey, August 19 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. , a leading developer of microRNA-based diagnostic and therapeutic products, reported today its consolidated financial results for the quarter ended June 30, 2008 and business highlights. The company reported a 2008 second-quarter net loss of $3.7 million, or $0.31 per ordinary share. The second-quarter result compares with a net loss of $2.3 million, or $0.19 per ordinary share, for the...
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Garry Menzel, Ph.D., as Executive Vice President of Corporate Development and Finance. Dr. Menzel brings a very strong background in global biotechnology finance practices to Regulus. "We are delighted to welcome Garry to Regulus. I have known...
